Form 8-K - Current report:
SEC Accession No. 0000950170-23-028900
Filing Date
2023-06-20
Accepted
2023-06-20 15:45:46
Documents
12
Period of Report
2023-06-13
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K inkt-20230613.htm   iXBRL 8-K 65738
  Complete submission text file 0000950170-23-028900.txt   186475

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT inkt-20230613_lab.xml EX-101.LAB 13904
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT inkt-20230613.xsd EX-101.SCH 2481
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT inkt-20230613_pre.xml EX-101.PRE 10238
6 EXTRACTED XBRL INSTANCE DOCUMENT inkt-20230613_htm.xml XML 4885
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40908 | Film No.: 231024888
SIC: 2836 Biological Products, (No Diagnostic Substances)